Saturday, February 7, 2026

Microsoft: Analysts Anticipate Q4 Earnings Per Share Of $2.29

Microsoft (NASDAQ: MSFT) will be reporting its fiscal fourth quarter financials today after markets close. Analysts have a consensus $344 12-month price target on the company, via a total of 52 analysts, with 19 analysts having strong buy ratings. 30 analysts meanwhile have buy ratings and three analysts have hold ratings. The street high sits at a $426 price target, and the lowest target sits at $252.

24 analysts have revenue estimates for the fourth quarter. The mean revenue estimate between all 24 analysts is $52.39 billion; this number is flat year to date now. The highest revenue estimate is $52.9 billion, while the lowest is $51.74 billion.

Onto EBITDA estimates, there are currently only six analysts who have fourth-quarter EBITDA estimates. The mean is currently $25.1 billion, with this number having been revised downwards from $25.4 billion at the start of the year. Street high is a $25.34 billion EBITDA estimate and the lowest is $24.88 billion.

Analysts estimate that quarterly earnings per share will come in at $2.29, with this number being revised steadily down since the start of the year. Street high is $2.35, and the lowest estimate is $2.24 per share for the quarter.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to the organizations discussed. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Silver Is a Wild Animal, Gold Heads for $6,000 in 2026 | Craig Hemke

Is This the End of the Gold and Silver Rally? | Peter Grandich

Why Gold And Silver Stay High Even After Rate Cuts | Todd Bubba Horwitz

Recommended

TomaGold Confirms Presence Of Berrigan Deep Zone Following Geophysics

Antimony Resources Reports Massive Stibnite Mineralization Over 25 Metres At Marcus (West) Zone

Related News

Canaccord Initiates Coverage On Else Nutrition With C$6.50 Price Target

This morning, Canaccord Genuity initiated coverage on Else Nutrition (TSXV: BABY) with a C$6.50 price...

Monday, December 7, 2020, 04:26:00 PM

Cresco Labs: Stifel Slashes Price Target From $30 To $8 Following Poor Q4 Results

On March 23rd, Cresco Labs (CSE: CL) announced its fourth-quarter financial results, which disappointed many...

Friday, March 25, 2022, 03:39:00 PM

Argonaut Gold: BMO Drops Target To $1.00 After Messy Q2 Results

On August 10, Argonaut Gold (TSX: AR) reported its second quarter financial results. The company...

Sunday, August 14, 2022, 01:13:00 PM

Canaccord Cuts Kinross Gold’s Price Target To $9.50

Last week, Kinross Gold Corporation (TSX: K) announced the suspension of its Russian operations. The...

Monday, March 7, 2022, 10:22:35 AM

PI Financial: US Cannabis Sector Showcased Strong Q2 Earnings

Earlier this month PI Financial came out with their post-second-quarter U.S cannabis update, in which...

Sunday, September 18, 2022, 01:20:00 PM